Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)

Abstract

BackgroundThe aim of our study was to investigate the clinical features and expression levels of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).MethodsWe retrospectively investigated the clinical features of 26 consecutive patients with LGSC who underwent primary staging or debulking surgery between April 2005 and June 2013 in our center; concomitant primary high-grade serous ovarian cancer (HGSC) patients were randomly selected at a 2:1 ratio for comparison. Tissue microarrays were constructed from the LGSC and HGSC specimens, and the expression levels of six hormone receptors in the hypothalamic pituitary-gonadal axis were analyzed by immunohistochemistry.ResultsThe median (range) age of patients with LGSC was 54 (27–77) years. According to the FIGO staging system, the cases were distributed as follows: stage I, 6 (23.1%); stage II, 0 (0%); stage III, 19 (73.1%); and stage IV, 1 (3.8%). The 2-year and 5-year overall survival rates for LGSC were 91.8% and 67.5%, respectively. The expression levels of the hormone receptors were as follows: ER, 80.8%; PR, 34.6%; AR, 53.8%; FSHR, 84.0%; LHR, 65.4%; and GnRHR, 100%. Hormone receptor-positive patients had a better prognosis compared with hormone receptor-negative patients, but the difference was not significant.ConclusionsOur study presented a higher overall survival rate and distinctive hormone receptor expression levels of LGSC patients compared with the HGSC cohort. Patients with positive hormone receptor expression tended to have a better prognosis than the corresponding hormone receptor negative patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-016-0300-5) contains supplementary material, which is available to authorized users.

Synthesis and Evaluation of 18F-Labeled Peptide for Gonadotropin-Releasing Hormone Receptor Imaging

“…Negative (no primary antibody) controls were included in the staining experiment. The cytoplasmic staining of the GnRH receptor was recorded as negative, weak, moderate, and strong [25].…”

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

“…There is also a relatively high proportion of estrogen receptor‐positive/progesterone receptor‐positive cancers (Fig. ), leading to the use of hormonal therapy in this specific ovarian cancer subgroup. In contrast to HGSOC, high CNAs and mutations in TP53 are rare; LGSOC does not seem to be related to BRCA1 / BRCA2 gene mutations.…”

Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer

“…A recent study showed that nearly 90% of patients with high-grade serous ovarian cancer were GnRH receptor-positive [ 24 ]. In another study, it was demonstrated that all low-grade (100%) and about 82% high-grade serous ovarian cancer showed GnRH receptor expression [ 25 ]. The receptor binding abilities differ between gonadotropic cells in the pituitary and cancer cells.…”